RESVERLOGIX

Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners... Resverlogix is a pioneer in the landscape of epigenetics. Today, apabetalone - discovered in 2006 - is the world leader in a new class of drugs designed to regulate gene expression through the inhibition of bromodomain and extraterminal domain (BET) proteins. Through this mechanism, we believe we can improve the lives of our patients by restoring biological functions - altered by serious illnesses such as cardiovascular disease - to a healthy state. The prevalence of BET proteins in the human body allows apabetalone to simultaneously target multiple disease-causing biological processes - leading a new paradigm shift in the treatment of chronic disease... Resverlogix (TSX: RVX), founded in 2001 by Donald McCaffrey and Norman Wong, focuses on the development of therapeutics for disease states with..

Also known as: Resverlogix Corp.

Primary location: Calgary Canada